Jeremy Green
CIK 1650527 · last filed 2026-08-07
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$463.80M
Companies
28
Total Filings
119
Lifetime Open-Market Net
$556.62M
Filer Profile
Reported Address
ONE LETTERMAN DRIVEBUILDING D, SUITE D3-300
SAN FRANCISCO, CA 94129
Related Filers
Redmile Group, LLC — 196 joint filings, latest 2026-08-07
RedCo II Master Fund, L.P. — 16 joint filings, latest 2026-04-23
ARRAY BIOPHARMA INC — 12 joint filings, latest 2016-09-30
Redmile Biopharma Investments II, L.P. — 3 joint filings, latest 2023-09-21
Attovia Therapeutics, Inc. — 2 joint filings, latest 2026-08-07
Beam Therapeutics Inc. — 2 joint filings, latest 2020-02-11
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses.
View filings on SEC EDGAR.
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ATTO | 10%+ Owner | 2,165,708 | $22.79 | $49.36M | $30.60M | 1 | 2026-08-07 |
| FATE | Director | 12,884,277 | $2.31 | $29.76M | $210.71M | 21 | 2026-06-15 |
| STTK | Director | 5,615,489 | $6.20 | $34.82M | $119.34M | 10 | 2025-08-26 |
| IGM Biosciences, Inc. (IGMS) Delisted | Director | 0 | $1.27 | $0 | $12.90M | 31 | 2025-08-15 |
| ADCT | 10%+ Owner | 28,762,443 | $1.07 | $30.78M | $8.41M | 4 | 2024-12-13 |
| Augmedix, Inc. (AUGX) Delisted | Director | 16,421,788 | $2.35 | $38.59M | $13.00M | 8 | 2024-06-18 |
| ABSI | Director | 8,262,136 | $8.21 | $67.83M | $62.00M | 4 | 2024-06-14 |
| Science 37 Holdings, Inc. (SNCE) Delisted | Director | 0 | $5.75 | $0 | $0 | 6 | 2024-03-13 |
| MedAvail Holdings, Inc. (MDVL) Delisted | Director | 1,074,046 | $1.80 | $1.93M | $0 | 2 | 2022-07-06 |
| Invivyd, Inc. (ADGI) Delisted | 10%+ Owner | 1,920,960 | $4.64 | $8.91M | $49.98M | 1 | 2021-08-12 |
| Verve Therapeutics, Inc. (VERV) Delisted | 10%+ Owner | 1,936,530 | $11.13 | $21.55M | $39.90M | 1 | 2021-06-23 |
| APRE | 10%+ Owner | 88,436 | $0.77 | $68.4K | -$5.58M | 1 | 2021-02-16 |
| KYMR | 10%+ Owner | 1,630,660 | $114.96 | $187.46M | $0 | 1 | 2020-08-25 |
| Kalaris Therapeutics, Inc. (ALVR) Delisted | 10%+ Owner | 35,799 | $9.81 | $351.2K | $0 | 1 | 2020-08-05 |
| ANNX | 10%+ Owner | 1,596,222 | $3.94 | $6.29M | $0 | 1 | 2020-07-30 |
| Repare Therapeutics Inc. (RPTX) Delisted | 10%+ Owner | 1,586,174 | $2.65 | $4.20M | $0 | 1 | 2020-06-25 |
| Neurogene Inc. (NLTX) Delisted | 10%+ Owner | 1,002,986 | $13.96 | $14.00M | $3.58M | 1 | 2020-04-06 |
| BEAM | 10%+ Owner | 1,161,458 | $23.99 | $27.86M | $0 | 1 | 2020-02-11 |
| Akero Therapeutics, Inc. (AKRO) Delisted | 10%+ Owner | 743,802 | $54.65 | $40.65M | $0 | 1 | 2019-06-24 |
| Atreca, Inc. (BCEL) Delisted | 10%+ Owner | 715,306 | $0.15 | $107.3K | $0 | 1 | 2019-06-24 |
| STOK | 10%+ Owner | 671,808 | $29.03 | $19.50M | $0 | 1 | 2019-06-24 |
| ALDER BIOPHARMACEUTICALS INC (ALDR) Delisted | Director | 8,244,896 | — | — | $0 | 3 | 2019-05-24 |
| TCR2 THERAPEUTICS INC. (TCRR) Delisted | 10%+ Owner | 807,256 | $1.48 | $1.19M | $0 | 1 | 2019-02-21 |
| VAPOTHERM INC (VAPO) Delisted | 10%+ Owner | 102,085 | $2.17 | $221.5K | $0 | 1 | 2018-11-16 |
| REPL | 10%+ Owner | 779,655 | $12.92 | $10.07M | $0 | 1 | 2018-07-25 |
| Allakos Inc. (ALLK) Delisted | 10%+ Owner | 1,009,090 | $0.33 | $332.1K | $0 | 1 | 2018-07-24 |
| Syros Pharmaceuticals, Inc. (SYRS) Delisted | 10%+ Owner | 8,476 | $0.00 | $3 | $10.82M | 1 | 2016-07-07 |
| AMICUS THERAPEUTICS, INC. (FOLD) Delisted | 10%+ Owner | 12,956,446 | $14.49 | $187.74M | $954.7K | 1 | 2016-06-13 |
Recent Filings · Page 2 of 12
119 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-12-26 | FATE | Mixed | +112,662 | $189.3K | EDGAR |
| 2024-12-16 | FATE | Conv (C) | +60,220 | $0 | EDGAR |
| 2024-12-13 | ADCT | Buy (P) | +600,000 | $1.83M | EDGAR |
| 2024-12-06 | ADCT | Mixed | +75,960 | $157.2K | EDGAR |
| 2024-10-04 | — | Disp (D) | −128,344,688 | -$301.61M | |
| 2024-10-02 | IGM Biosciences, Inc. (IGMS) Delisted | Grant (A) | +3,468 | $0 | EDGAR |
| 2024-07-03 | ADCT | Buy (P) | +2,400,000 | $6.74M | EDGAR |
| 2024-07-02 | IGM Biosciences, Inc. (IGMS) Delisted | Grant (A) | +3,468 | $0 | EDGAR |
| 2024-06-21 | STTK | Grant (A) | — | $0 | EDGAR |
| 2024-06-18 | Augmedix, Inc. (AUGX) Delisted | Grant (A) | +25,758 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.